S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Albireo Pharma Stock Forecast, Price & News

+0.18 (+0.52 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $35.06
50-Day Range
MA: $38.43
52-Week Range
Now: $35.06
Volume101,000 shs
Average Volume172,700 shs
Market Capitalization$668.84 million
P/E RatioN/A
Dividend YieldN/A
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Albireo Pharma logo


Overall MarketRank

1.53 out of 5 stars

Medical Sector

385th out of 1,923 stocks

Pharmaceutical Preparations Industry

200th out of 773 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ALBO
Phone(857) 254-5555



Sales & Book Value

Annual Sales$9.64 million
Book Value$7.34 per share


Net Income$-62,720,000.00
Net Margins-751.53%


Market Cap$668.84 million
Next Earnings Date3/1/2021 (Estimated)
+0.18 (+0.52 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

How has Albireo Pharma's stock been impacted by Coronavirus?

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALBO stock has increased by 98.9% and is now trading at $35.06.
View which stocks have been most impacted by COVID-19

Is Albireo Pharma a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Albireo Pharma?

Wall Street analysts have given Albireo Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Albireo Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Albireo Pharma

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) released its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($1.96) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.51) by $0.45. The biopharmaceutical company earned $2.13 million during the quarter, compared to analyst estimates of $1.90 million. Albireo Pharma had a negative trailing twelve-month return on equity of 71.22% and a negative net margin of 751.53%.
View Albireo Pharma's earnings history

What price target have analysts set for ALBO?

8 Wall Street analysts have issued 1-year price targets for Albireo Pharma's stock. Their forecasts range from $52.00 to $81.00. On average, they anticipate Albireo Pharma's stock price to reach $69.43 in the next year. This suggests a possible upside of 98.0% from the stock's current price.
View analysts' price targets for Albireo Pharma
or view Wall Street analyst' top-rated stocks.

Who are some of Albireo Pharma's key competitors?

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the following people:
  • Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 58, Pay $838.51k)
  • Dr. Patrick T. Horn, Chief Medical Officer (Age 66, Pay $588.46k)
  • Ms. Pamela Stephenson M.P.H., Chief Commercial Officer (Age 53, Pay $469.19k)
  • Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
  • Dr. Jan P. Mattsson, Chief Scientific Officer & MD (Sweden) and Co-Founder (Age 57)
  • Mr. Simon N.R. Harford, CFO & Treasurer (Age 60)
  • Mr. Jason G. Duncan, Chief Legal Officer, Gen. Counsel & Sec. (Age 46)
  • Ms. Michelle Graham, Chief HR Officer (Age 54)
  • Dr. Kristina TorfgÃ¥rd, VP & Global Project Head
  • Ms. Martha J. Carter, Chief Regulatory Officer (Age 69)

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Pacer Advisors Inc. (0.01%). Company insiders that own Albireo Pharma stock include Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc and Simon NR Harford.
View institutional ownership trends for Albireo Pharma

Which institutional investors are buying Albireo Pharma stock?

ALBO stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Albireo Pharma
or or view top insider-buying stocks.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $35.06.

How big of a company is Albireo Pharma?

Albireo Pharma has a market capitalization of $668.84 million and generates $9.64 million in revenue each year. The biopharmaceutical company earns $-62,720,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis. Albireo Pharma employs 55 workers across the globe.

What is Albireo Pharma's official website?

The official website for Albireo Pharma is www.albireopharma.com.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at (857) 254-5555 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.